-
21.发明公开유럽종 포도의 씨 추출물 및 레바미피드를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물 有权用于预防或治疗包含VITIS VINIFERA PIP提取物和雷巴米地的含盐酸盐的药物组合物
公开(公告)号：KR1020120032649A
公开(公告)日：2012-04-06
申请号：KR1020100094091
申请日：2010-09-29
Applicant: 한림제약(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing rebamipide and Vitis vinifera seed extract is provided to prevent or treat rheumatoid arthritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatoid arthritis contains rebamipide and Vitis vinifera seed extract. The pharmaceutical composition is orally administered in the form of a tablet or capsule. The dosage of rebamipide is 0.3 mg/kg a day.
Abstract translation: 目的：提供含有瑞巴派特和葡萄种子提取物的药物组合物，以预防或治疗类风湿性关节炎。 构成：用于预防或治疗类风湿性关节炎的药物组合物含有瑞巴派特和葡萄籽种子提取物。 药物组合物以片剂或胶囊的形式口服给药。 瑞巴派特的剂量为每天0.3mg / kg。
-
公开(公告)号：KR1020120021239A
公开(公告)日：2012-03-08
申请号：KR1020110086459
申请日：2011-08-29
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61P35/00
CPC classification number: A61K31/4704
Abstract: PURPOSE: A composition containing rebamipide for preventing or treating cancer or immune diseases is provided to suppress Th17 cell differentiation and to enhance immune regulatory T cell activity. CONSTITUTION: A composition for preventing or treating cancer or immune diseases contains rebamipid compounds or pharmaceutically acceptable salt thereof as an active ingredient. The immune diseases include autoimmune disease, inflammatory disease, and transplantation rejection. A method for reducing or suppressing differentiation of immature T cells into Th17 cell in vitro comprises a step of treating rebamipid compounds or pharmaceutically acceptable salt thereof.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的瑞巴派特的组合物以抑制Th17细胞分化并增强免疫调节性T细胞活性。 构成：用于预防或治疗癌症或免疫疾病的组合物含有雷米帕派化合物或其药学上可接受的盐作为活性成分。 免疫疾病包括自身免疫性疾病，炎性疾病和移植排斥反应。 用于在体外降低或抑制未成熟T细胞分化成Th17细胞的方法包括处理rebamipid化合物或其药学上可接受的盐的步骤。
-
公开(公告)号：KR1020110137588A
公开(公告)日：2011-12-23
申请号：KR1020100057601
申请日：2010-06-17
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract and pharmaceutically acceptable carrier is provided to prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract has 80-130 of procyanidolic value(PCV) and contains less than 30% of (+)catechin and (-) epicatechin and 95-105% of proanthocyanidin content. A method for preparing the extract comprises: a step of mixing pulverized Vitis vinifera seed and a mixture solvent of acetone and water and isolating at room temperature; a step of filtering the extract and distilling the filtered liquid to remove acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物和药学上可接受的载体的药物组合物以预防和治疗肥胖症。 构成：用于预防或治疗肥胖症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 提取物具有80-130原花青素值（PCV），并且含有少于30％的（+）儿茶素和（ - ）表儿茶素和95-105％的原花色素含量。 一种制备提取物的方法包括：将经粉碎的葡萄种子和丙酮和水的混合溶剂混合并在室温下分离的步骤; 过滤提取物并蒸馏过滤的液体以除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤步骤。
-
24.发明授权
公开(公告)号：KR101044433B1
公开(公告)日：2011-06-27
申请号：KR1020080087109
申请日：2008-09-04
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis
vinifera )의 씨 추출물의 개선된 제조방법을 제공한다. 또한, 본 발명은 유럽종 포도(
Vitis
vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 류마티스 관절염-
公开(公告)号：KR1020110021016A
公开(公告)日：2011-03-04
申请号：KR1020090078547
申请日：2009-08-25
Applicant: 가톨릭대학교 산학협력단 , 한림제약(주)
IPC: A61K31/4704 , A61P19/02 , A61K9/20 , A61K9/48
CPC classification number: A61K31/4704
Abstract: PURPOSE: A pharmaceutical composition containing rabamipide and pharmaceutically acceptable carrier is provided to prevent or treat rheumatoid arthritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatoid arthritis contains rabamipid and pharmaceutically acceptable carrier. The pharmaceutical composition is used for oral administration. The pharmaceutical composition is formed in oral solid dosage. The pharmaceutical composition has rabamipid formulated in 0.5-50 mg/kg of unit dosage form.
Abstract translation: 目的：提供含有拉巴米特和药学上可接受的载体的药物组合物，以预防或治疗类风湿性关节炎。 构成：用于预防或治疗类风湿性关节炎的药物组合物含有拉帕米特和药学上可接受的载体。 药物组合物用于口服给药。 药物组合物以口服固体剂量形成。 药物组合物具有配制在0.5-50mg / kg单位剂型中的拉巴米特。
-
Patent Agency Ranking
公开(公告)号：KR101858346B1
公开(公告)日：2018-05-16
申请号：KR1020160086199
申请日：2016-07-07
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K39/395 , A61K31/713 , A61K39/00 , G01N33/50
CPC classification number: A61K31/713 , A61K39/00 , A61K39/395 , A61K48/00 , G01N33/50
Abstract: 본발명은 RIPK 억제제를유효성분으로포함하는면역질환치료용조성물에관한것으로, 면역질환이유발된질병조직에서 RIPK의발현이과발현되어있는것으로나타났고, 면역질환의동물모델에 RIPK 억제제를투여할경우면역질환의증상이완화및 개선되는것으로나타났으며염증성사이토카인및 병인성사이토카인의생성이억제되는것으로나타났다. 따라서본 발명은 RIPK 억제제를면역질환을효과적으로예방및 치료할수 있는효과가있다.
-
公开(公告)号：KR1020160040165A
公开(公告)日：2016-04-12
申请号：KR1020160038523
申请日：2016-03-30
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61K9/20 , A61K9/50
Abstract: 본발명은고지혈증및 이와관련된질환을예방또는치료하는데사용되는레바미피드의약학적용도에관한것으로, 자세하게는레바미피드를유효성분으로포함하는고지혈증및 이와관련된질환의예방또는치료용조성물에관한것이다. 본발명에따른레바미피드화합물은대식세포에서분비하는고지혈증유발염증성사이토카인인 TNF-a, IL-6 및 IL-1b의생성을억제시키며; 동맥경화반(Artherosclerotic plaque) 전구세포를형성하는거품세포(Foam cell)의생성을억제시키고; 혈액내 총-콜레스테롤, LDL-콜레스테롤및 중성지방수치를낮춤으로서혈액지질을개선시키며; 지방간을개선시키고; B 세포의활성을억제시키며; 동맥경화반생성을가속화시키는 Th17의발현감소와더불어염증반응을제어할수 있는 Treg 세포의발현을증대시킬수 있다. 따라서레바미피드화합물은상기와같은다양한기작을통해고지혈증및 이와관련된동맥경화증, 심부전증, 고혈압성심장질환등을예방또는치료할수 있는약학적조성물로유용하게사용할수 있다. 또한, 약물에대한독성및 부작용도없어장기간복용시에도안심하고사용할수 있으며, 체내에대해안정한효과가있다.
Abstract translation: 本发明涉及瑞巴派特在预防或治疗高脂血症和相关疾病中的应用。 特别地，本发明涉及用于预防或治疗高脂血症和相关疾病的组合物，其包含瑞巴派特作为活性成分。 瑞巴派特化合物抑制由巨噬细胞分泌的引起高脂血症的炎性细胞因子TNF-α，IL-6和IL-1b的产生; 抑制形成动脉粥样硬化斑块前体细胞的泡沫细胞的产生; 通过降低血液中总胆固醇，LDL-胆固醇和甘油三酯的含量来改善血脂特征; 改善脂肪肝; 并抑制B细胞活性; 减少Th17的表达，促进动脉粥样硬化斑块的产生，同时增加能够控制炎症反应的Treg细胞的表达。 因此，雷帕匹特化合物可以用于通过这些各种机制预防或治疗高脂血症和相关疾病如动脉粥样硬化，心力衰竭和高血压性心脏病的药物组合物。 此外，雷巴米特化合物没有毒副作用，即使在长期给药的情况下也可以安全使用，并且在体内稳定。
-
公开(公告)号：KR1020140016848A
公开(公告)日：2014-02-10
申请号：KR1020130090687
申请日：2013-07-31
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61P3/06 , A61P3/00
CPC classification number: A61K31/4704
Abstract: The present invention relates to the pharmaceutical use of rebamipide used for preventing or treating hyperlipidemia and diseases therewith and more specifically, to a composition containing rebemipide as an active ingredient for preventing or treating hyperlipidemia and diseases associated therewith. The rebamipidie compound according to the present invention: suppresses the formation of TNF-a, IL-6, and IL-1b, which are inflammatory cytokines inducing hyperlipidemia and secreted by macrophages; inhibits the generation of foam cells forming atherosclerotic plaque precursor cells; improves blood lipid by reducing the levels of total cholesterol, LDL-cholesterol, and triglycerides in blood; improves a fatty liver; inhibits B cell activities; decreases the expression of Th17 accelerating atherosclerotic plaque formation; and increases the expression of Treg cells controlling the inflammatory response. Thus, the rebamipide compound can be useful as a pharmaceutical composition for preventing or treating hyperlipidemia and diseases associated therewith including atherosclerosis, heart failure, hypertensive cardiac diseases through various mechanisms. Also, the composition has no toxicity or side effect, thereby being safe to use for a long period and stable in the body.
Abstract translation: 本发明涉及用于预防或治疗高脂血症及其疾病的雷巴米特的药物用途，更具体地说，涉及含有作为预防或治疗高脂血症及与其相关疾病的活性成分的瑞米派特的组合物。 根据本发明的反刍动物化合物：抑制TNF-α，IL-6和IL-1b的形成，其是诱导高脂血症并由巨噬细胞分泌的炎性细胞因子; 抑制形成动脉粥样硬化斑块前体细胞的泡沫细胞的产生; 通过降低血液中总胆固醇，低密度脂蛋白胆固醇和甘油三酯的水平来改善血脂; 改善脂肪肝; 抑制B细胞活性; 降低Th17加速动脉粥样硬化斑块形成的表达; 并增加控制炎症反应的Treg细胞的表达。 因此，雷巴米特化合物可用作通过各种机制预防或治疗高脂血症及其相关疾病的药物组合物，包括动脉粥样硬化，心力衰竭，高血压性心脏病。 另外，该组合物无毒副作用，长期使用安全，体内稳定。
-
公开(公告)号：KR1020130116825A
公开(公告)日：2013-10-24
申请号：KR1020130041359
申请日：2013-04-16
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61K38/17 , C12N15/63 , C12N15/12
CPC classification number: A61K31/353 , A61K38/1709 , Y10S514/825
Abstract: PURPOSE: An antioxidant is provided to effectively enhance the expression of Rcan3 gene and to be used as an immunosuppressive agent for treating or preventing immune diseases because Rcan3 protein suppresses calcineurin pathway. CONSTITUTION: An antioxidant increases the expression of Rcan3 gene. The antioxidant is rebamipide or polyphenol compounds. The polyphenol compounds are proanthocyanidin. A method for increasing the expression of Rcan3 in vitro comprises the step of treating cells with the antioxidant. A composition for preventing or treating immune disease contains Rcan3 gene or protein as an active ingredient.
Abstract translation: 目的：提供抗氧化剂以有效增强Rcan3基因的表达，并用作免疫抑制剂，用于治疗或预防免疫疾病，因为Rcan3蛋白抑制钙调神经磷酸酶途径。 构成：抗氧化剂增加Rcan3基因的表达。 抗氧化剂是瑞巴派特或多酚化合物。 多酚化合物是原花色素。 在体外增加Rcan3表达的方法包括用抗氧化剂处理细胞的步骤。 用于预防或治疗免疫疾病的组合物含有Rcan3基因或蛋白质作为活性成分。
-
公开(公告)号：KR1020130044155A
公开(公告)日：2013-05-02
申请号：KR1020120114823
申请日：2012-10-16
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61P3/04 , A61P3/00
CPC classification number: A61K31/4704 , A23L33/10 , A23V2002/00 , A61K9/0019 , A23V2200/332
Abstract: PURPOSE: Obesity preventing or treating composition comprising rebamipide is provided to reduce LDL cholesterol levels and to increase HDL cholesterol levels. CONSTITUTION: Obesity preventing or treating composition comprising rebamipide comprises rebamipide compounds or salt of the rebamipide compounds. Rebamipide is capable of reducing weight, fat cells, total cholesterol levels, glucose and LDL cholesterol levels. Rebamipide has anti-obesity activiation through an action of changing white fat into brown fat. Rebamipide increases the activation of amplification of a regulatory T cell.
Abstract translation: 目的：提供包含瑞巴派特的肥胖症预防或治疗组合物以降低LDL胆固醇水平和提高HDL胆固醇水平。 构成：包含瑞巴派特的肥胖症预防或治疗组合物包括雷巴米特化合物或雷巴米特化合物的盐。 瑞巴米特能够减轻体重，脂肪细胞，总胆固醇水平，葡萄糖和低密度脂蛋白胆固醇水平。 瑞巴米特通过将白脂肪变成棕色脂肪的作用，具有抗肥胖作用。 瑞巴米特可增加调节性T细胞扩增的活化。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.027 seconds)
